卡格列净通过诱导类禁食与类夏眠代谢模式调控糖尿病肾脏病的代谢重编程
研究对35例(11例女性)接受卡格列净100 mg/日治疗12周的2型糖尿病合并肾病患者进行血浆代谢组学分析,并在db/db小鼠中验证。卡格列净降低HbA1c和尿白蛋白/肌酐比值,诱导类禁食与类夏眠代谢模式,甘氨酸补充可改善db/db小鼠肾脏病变及人近端小管细胞凋亡。
要点
- 卡格列净治疗12周降低2型糖尿病合并肾病患者HbA1c和尿白蛋白/肌酐比值。
- 卡格列净下调糖酵解、上调脂肪酸氧化,并显著上调甘氨酸。
- 甘氨酸补充通过AMPK/mTOR通路改善db/db小鼠肾脏病变及人近端小管细胞凋亡。
核心结论
- 卡格列净通过诱导类禁食与类夏眠代谢模式改善糖尿病肾脏病。
- 甘氨酸补充可改善糖尿病肾脏病,其有益效应可能源于AMPK/mTOR通路的激活。
研究设计与样本
- 对35例(11例女性)接受卡格列净100 mg/日治疗的2型糖尿病合并肾病患者,在基线和12周随访时进行血浆非靶向和靶向代谢组学检测。
- 利用db/db小鼠系统获取卡格列净对肾脏关键代谢物和通路影响的快照。
- 研究甘氨酸补充对db/db小鼠和人近端小管上皮细胞(HK-2)的影响。
主要发现
- 卡格列净治疗12周使HbA1c从49.0(44.0-57.0)mmol/mol(7.9%[7.10-9.20%])降至42.2(39.7-47.7)mmol/mol(6.8%[6.40-7.70%])。
- 卡格列净治疗12周使尿白蛋白/肌酐比值从67.8(45.9-159.0)mg/mmol降至47.0(26.0-93.6)mg/mmol。
- 非靶向代谢组学显示糖酵解下调、脂肪酸氧化上调,靶向代谢组学显示甘氨酸显著上调。
- db/db小鼠肾脏发生显著代谢重编程,卡格列净调节其糖、脂和氨基酸代谢,甘氨酸、丝氨酸和苏氨酸代谢通路及甘氨酸代谢物在治疗肾脏中显著上调。
- 甘氨酸补充通过抑制摄食、改善胰岛素敏感性和降低血糖改善db/db小鼠肾脏病变,并通过AMPK/mTOR通路改善人近端小管细胞凋亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Sodium-glucose co-transporter 2 (SGLT2) inhibitors (SGLT2i) are antihyperglycaemic drugs that protect the kidneys of individuals with type 2 diabetes mellitus. However, the underlying mechanisms mediating the renal benefits of SGLT2i are not fully understood. Considering the fuel switches that occur during therapeutic SGLT2 inhibition, we hypothesised that SGLT2i induce fasting-like and aestivation-like metabolic patterns, both of which contribute to the regulation of metabolic reprogramming in diabetic kidney disease (DKD). METHODS: Untargeted and targeted metabolomics assays were performed on plasma samples from participants with type 2 diabetes and kidney disease (n=35, 11 women) receiving canagliflozin (CANA) 100 mg/day at baseline and 12 week follow-up. Next, a systematic snapshot of the effect of CANA on key metabolites and pathways in the kidney was obtained using db/db mice. Moreover, the effects of glycine supplementation in db/db mice and human proximal tubular epithelial cells (human kidney-2 [HK-2]) cells were studied. RESULTS: Treatment of DKD patients with CANA for 12 weeks significantly reduced HbA1c from a median (interquartile range 25-75%) of 49.0 (44.0-57.0) mmol/mol (7.9%, [7.10-9.20%]) to 42.2 (39.7-47.7) mmol/mol (6.8%, [6.40-7.70%]), and reduced urinary albumin/creatinine ratio from 67.8 (45.9-159.0) mg/mmol to 47.0 (26.0-93.6) mg/mmol. The untargeted metabolomics assay showed downregulated glycolysis and upregulated fatty acid oxidation. The targeted metabolomics assay revealed significant upregulation of glycine. The kidneys of db/db mice undergo significant metabolic reprogramming, with changes in sugar, lipid and amino acid metabolism; CANA regulated the metabolic reprogramming in the kidneys of db/db mice. In particular, the pathways for glycine, serine and threonine metabolism, as well as the metabolite of glycine, were significantly upregulated in CANA-treated kidneys. Glycine supplementation ameliorated renal lesions in db/db mice by inhibiting food intake, improving insulin sensitivity and reducing blood glucose levels. Glycine supplementation improved apoptosis of human proximal tubule cells via the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway. CONCLUSIONS/INTERPRETATION: In conclusion, our study shows that CANA ameliorates DKD by inducing fasting-like and aestivation-like metabolic patterns. Furthermore, DKD was ameliorated by glycine supplementation, and the beneficial effects of glycine were probably due to the activation of the AMPK/mTOR pathway.
引用
- Shao M, Chen D, Wang Q, et al. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns. Diabetologia. 2024. PMID: 38236410. doi:10.1007/s00125-023-06078-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。